Dr Jason Lickliter trained as a medical oncologist in Australia and at the University of Minnesota and is
currently the Chief Medical Officer at Nucleus Network, a multi-centre phase 1 clinical trials
organization. He began working with Amplia on the AMP945 phase 1 trial in healthy volunteers and has
since become an adviser for the ACCENT trial. Dr Lickliter has extensive experience in designing and
implementing early-phase patient and healthy-volunteer clinical trials, including the integration of
biomarker studies and advanced imaging into clinical research.